The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play essential roles in SCLC cell proliferation and survival. METHODS: The inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Liying, Bian, Xing, Lin, Wenchu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568419/
https://www.ncbi.nlm.nih.gov/pubmed/33069237
http://dx.doi.org/10.1186/s13046-020-01728-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568419/
https://www.ncbi.nlm.nih.gov/pubmed/33069237
http://dx.doi.org/10.1186/s13046-020-01728-2

Ejemplares similares